SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should State Street SPDR S&P 600 Small Cap Value ETF (SLYV) Be on Your Investing Radar?

Should SPDR S&P 600 Small Cap Value ETF (SLYV) Be on Your Investing Radar?

Retail sentiment for Carvana (CVNA) remained 'bearish'&nbsp;late Wednesday despite the online used-car retailer's strong earnings report, with some Stocktwits users voicing skepticism, suggesting the results seem almost too good to be true and may warrant a deeper investigation.Carvana was among the top 10 trending tickers, with message volume around the stock surging over 375% in the last 24 hours, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:1262/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_31_at_7_47_29_AM_png_3367633f96.webp" alt="Screenshot 2025-07-31 at 7.47.29 AM.png" width="1262" height="154"><figcaption>CVNA sentiment and message volume as of July 30 | Source: Stocktwits</figcaption></figure>The company said revenue in its second quarter rose 42% to $4.84 billion, and it sold a record 143,280 car units in the period. Analysts surveyed by FactSet were expecting revenue of $4.58 billion.Adjusted profit rose to $1.28 per share from $0.14 in the year-ago quarter. That, too, easily beat expectations of $1.17.Carvana has drawn increased investor interest in recent months as the used-car market heats up amid Trump-era tariffs. With buyers looking to hedge against potential price hikes, demand is shifting toward more affordable options, particularly used vehicles.However, a 64% stock gain year-to-date, and about 40% year-on-year sales growth in the preceding Q1 2025 and Q4 2024 are making&nbsp;some investors jittery."There's no way those books are legit. People are calling them out left and right," a user said. "They're worth more than some of the major car brands. It's impossible."<stembedurl>https://stocktwits.com/rainmaker1967/message/623116855</stembedurl>Carvana’s market capitalization stands at over $45 billion as of the last close. That’s more than that of Ford, Stellantis or Rivian.&nbsp;It is not the first time the company&nbsp;has stirred up such concerns. A Hindenberg report in January&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carvana-stock-volatile-after-hindenburg-short-report-that-alleges-accounting-manipulation/cW6v7r0RlB">accused</a> the e-commerce car company of accounting manipulation, including handing out millions of dollars in suspicious loan sales to undisclosed customers.Carvana said it has been subpoenaed by the Securities and Exchange Commission for information related to the Hindenburg report.Another Stocktwits user remarked in a lighter vein: "$CVNA the netflix special on this scam in 5 years will be a fun watch."&nbsp;<stembedurl>https://stocktwits.com/earlyretirmnt/message/623109216</stembedurl>Yet another said, “A collapse is coming. Be very diligent!”<stembedurl>https://stocktwits.com/gr8whitenorth/message/623138152</stembedurl>Notwithstanding these claims, <a href="https://stocktwits.com/symbol/CVNA">Carvana shares</a> rose 15% in extended trading, following the results."Looking toward the third quarter, as long as the environment remains stable, Carvana expects a sequential increase in retail units sold and Adjusted EBITDA of $2.0 to $2.2 billion for the full year 2025, an increase from $1.38 billion last year," the company statement said.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In an aerial view, a sign is posted on the exterior of a Carvana car vending machine on July 19, 2023 in Daly City, California.

SLYV
SPDR S&P 600 Small Cap Value ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SLYV News

SLYVSPDR S&P 600 Small Cap Value ETF